Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s695, 2025. DOI: 10.25251/m10xva58. Disponível em: https://skin.dermsquared.com/skin/article/view/3825. Acesso em: 2 may. 2026.